- Home
- LYEL vs BEATW Comparison
LYEL vs BEATW Comparison
Compare LYEL & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- BEATW
- Stock Information
- Founded
- LYEL 2018
- BEATW N/A
- Country
- LYEL United States
- BEATW United States
- Employees
- LYEL N/A
- BEATW 20
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- LYEL Health Care
- BEATW Technology
- Exchange
- LYEL Nasdaq
- BEATW Nasdaq
- Market Cap
- LYEL 263.9M
- BEATW N/A
- IPO Year
- LYEL 2021
- BEATW 2021
- Fundamental
- Price
- LYEL $0.65
- BEATW $0.65
- Analyst Decision
- LYEL Sell
- BEATW
- Analyst Count
- LYEL 2
- BEATW 0
- Target Price
- LYEL $1.00
- BEATW N/A
- AVG Volume (30 Days)
- LYEL 1.4M
- BEATW N/A
- Earning Date
- LYEL 02-26-2025
- BEATW N/A
- Dividend Yield
- LYEL N/A
- BEATW N/A
- EPS Growth
- LYEL N/A
- BEATW N/A
- EPS
- LYEL N/A
- BEATW N/A
- Revenue
- LYEL $63,000.00
- BEATW N/A
- Revenue This Year
- LYEL N/A
- BEATW N/A
- Revenue Next Year
- LYEL N/A
- BEATW N/A
- P/E Ratio
- LYEL N/A
- BEATW N/A
- Revenue Growth
- LYEL N/A
- BEATW N/A
- 52 Week Low
- LYEL $0.58
- BEATW N/A
- 52 Week High
- LYEL $3.26
- BEATW N/A
- Technical
- Relative Strength Index (RSI)
- LYEL 35.21
- BEATW N/A
- Support Level
- LYEL $0.60
- BEATW N/A
- Resistance Level
- LYEL $0.71
- BEATW N/A
- Average True Range (ATR)
- LYEL 0.06
- BEATW 0.00
- MACD
- LYEL 0.01
- BEATW 0.00
- Stochastic Oscillator
- LYEL 24.66
- BEATW 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.